Quratis큐라티스
348080 · KOSDAQ · ₩348080 · 큐라티스
- Market cap
- ₩41B
- Enterprise value
- ₩39B
- P/E
- —
- P/B
- 0.9×
- Dividend yield
- 0.0%
- ROE
- −47.8%
- Net margin
- −2,061.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−75.1% from the high
₩1,765Today: ₩3,100 – ₩3,335₩12,975
Returns
- 1W−1.2%
- 1M−21.4%
- 3M+61.7%
- 6M−57.4%
- YTD−71.6%
- 1Y−60.2%
- Volume today
- 9,631
- 0.2× the 20-day average
- Traded today
- ₩31M
- Listed shares
- 12,827,753
- EPS (12 months)
- −₩1,762
- Earnings yield −54.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-26.7% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Quratis stock overview
Quratis (큐라티스, KRX: 348080) is listed on KOSDAQ, in the Biotech & Pharma sector. Qurates is a South Korean vaccine developer built on a platform covering the full drug development process, from candidate discovery through clinical trials, approval and commercial production. Its shares closed at ₩3,225 on Oct 26, 2026, down 3.15% on the day, giving it a market value of ₩41B.
Key facts
- Market cap
- ₩41B
- Sector
- Biotech & Pharma
- Latest price change
- −3.15%
- As of
- Oct 26, 2026
- Main business
- Qurates is a South Korean vaccine developer built on a platform covering the full drug development process, from candidate discovery through clinical trials, approval and commercial production.
Quick answers about Quratis
- What does Quratis do?
- Qurates is a South Korean vaccine developer built on a platform covering the full drug development process, from candidate discovery through clinical trials, approval and commercial production. Its main pipeline includes QTP101, a booster vaccine for tuberculosis prevention aimed at adolescents and adults, QTP105, a vaccine against schistosomiasis, and QTP104, a next-generation self-amplifying mRNA COVID-19 vaccine. The company also offers CMO and CDMO services from its own bio plant to domestic and overseas drug developers, and conducts clinical trials in countries including the United States, South Africa, the Philippines and Burkina Faso.
- What is the market cap of Quratis?
- The market capitalisation of Quratis was ₩41B at the close on Oct 26, 2026.
- Who are the largest shareholders of Quratis?
- According to the latest official filings, the largest reported holders are Inventage Lab (40.91%, as of Aug 10, 2026); Peace2S Korea (13.06%, as of Aug 10, 2026); Wired Win-Win Growth Private Equity Fund (11.87%, as of Nov 5, 2025).
- When is the next earnings report from Quratis?
- Korean companies rarely announce results dates in advance. Based on when Quratis filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Qurates is a South Korean vaccine developer built on a platform covering the full drug development process, from candidate discovery through clinical trials, approval and commercial production. Its main pipeline includes QTP101, a booster vaccine for tuberculosis prevention aimed at adolescents and adults, QTP105, a vaccine against schistosomiasis, and QTP104, a next-generation self-amplifying mRNA COVID-19 vaccine. The company also offers CMO and CDMO services from its own bio plant to domestic and overseas drug developers, and conducts clinical trials in countries including the United States, South Africa, the Philippines and Burkina Faso.
Written by AI from the company's latest annual report.
- Korean name
- 큐라티스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김성준
- Founded
- Jul 2016
- Listed
- Jun 2023
- Listed shares
- 12,827,753
- Fiscal year ends
- Month 12
- Website
- quratis.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Trading Plan Report for Executives and Major Shareholders' Specific SecuritiesOct 8, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportAug 10, 2026
- 5%+ holding reportAug 10, 2026
- Insider shareholding reportAug 10, 2026
Titles in Korean until English translations are added.
Also known as: Quratis / 큐라티스 / 348080 / KRX:348080
Source: KRX statistical information